Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Accelerated Approval - what are the chances?
View:
Post by Eoganacht on Dec 08, 2022 1:28pm

Accelerated Approval - what are the chances?

8 out of 29 patients (28%) have hit at least 450 days completely cancer free. 
 
Remove the 12 undertreated from the calculation to see just the optimized resu ( these 12 are mostly little different from the first 3 half-dose patients from the phase 1b ) and you have these optimized results at 450 days:

8 out of 17 ( 47% ) patients cancer free (including 3 full dose phase 1 patients) and
6 out of 14 ( 43% ) patients cancer free (including only phase 2 patients)
 
Surely those numbers, along with the extremely high safety, should be enough for AA.
 
I'm sure the 6 phase 2 patients who no longer have bladder cancer think so.
Comment by N0taP00p on Dec 08, 2022 1:47pm
Certainly makes me want to buy more. :)
Comment by stocksnbonds458 on Dec 08, 2022 1:50pm
Well Eoganacht, apparently Immogene received Accelerated Approval with a 5% CR so hopefully we will be a sure thing.
Comment by Kingpin68 on Dec 08, 2022 1:52pm
SF, Thanks for putting up those stats removing the under treated. Very, very encouraging.
Comment by Kingpin68 on Dec 08, 2022 2:17pm
Sorry, that was Eog's post  And, how do we not get BTD and AA basd on those numbers. I keep buying when I can.
Comment by enriquesuave on Dec 08, 2022 2:38pm
Those are CR patients, plus we have PR patients some of which may end up CR if proven to have UTUC 
Comment by riverrrow on Dec 08, 2022 3:34pm
Wow!!!   Terrific cancer treatment numbers. This is the first time I've seen the numbers laid out like this from the recent clinical trial results.  Thanks for posting.  GLTA.
Comment by Oilminerdeluxe on Dec 08, 2022 3:58pm
Those are the numbers I have waited to see. Thank you very, very much. Hope the FDA likes them too.
Comment by Infinity on Dec 08, 2022 4:55pm
TSX.V had less than 42000 sold today.  Positive indication.  Nobody is willing to sell at these low prices.  All Long holders are aware that we have a winner in our hands.  Great study results.  I am sure, FDA is aware of initial 12 under treated patients who are still in the study knowing that this is the best treatment to avoid the worst case scenario of Cystectomy.  ...more  
Comment by ScienceFirst on Dec 08, 2022 4:47pm
Eoganacht... Excellent post.  Thanks for sharing. This is what I would have expected from an analyst like Ubbin covering TLT.   You deciphered our data in order to make a comparison between 2 subset groups (undertreated group versus optimized group).   This then allows us to compare the best subset group DR % against other Accelerated Approval winners like KEYTRUDA in our own ...more  
Comment by BlueFranky on Dec 08, 2022 5:43pm
Eoganacht... Thank you so much for arguably, the best post I've seen this year.. I do believe this needs to be sitting in front of the center on every screen Awesome!   
Comment by BlueFranky on Dec 08, 2022 5:46pm
...like I said, front and center! Thanks again Eoganacht.. for your post below, of this day: Accelerated Approval - what are the chances? 8 out of 29 patients (28%) have hit at least 450 days completely cancer free.    Remove the 12 undertreated from the calculation to see just the optimized resu ( these 12 are mostly little different from the first 3 half ...more  
Comment by CancerSlayer on Dec 08, 2022 7:42pm
  Thanks Eoganacht....Uddin certainly needs to do more homework next time ; ).   I stopped considering those undertreated in my "personal" calculations/investment decisions the day I heard they were undertreated (7/30/2020).  And looking forward to the day we can finally nix "optimized" from "optimized patients".   Though the terminology was ...more  
Comment by Yoly900 on Dec 08, 2022 9:56pm
WE WILL FAIL AND BE DELAYED TIL 4th quarter 2023 than 0.002. First we will hit 0.37 selloff back to 0.17 and than bull delays will be in affect Oct warrants will be extended agsin roger and company will rebuy and stock options WE WILL VOTE YES TO STOCK OPTIONS THATS BULL ALSO. One big VICIOUS CYCLE OH COVID VACCINE 2024 gotta love whst about all work 2 years time guess what nothing was done ...more  
Comment by ScienceFirst on Dec 08, 2022 8:05pm
What's even more in our favor is that the FDA doesn't only consider CRs but TRs (CR + PR).  So our TR for the optimized group is already above 50%. Considering what's at stake, bladder removal, anything that can delay its removal or that can preseve it, should be welcomed and offered as a new alternative to patients.  That's the spirit of the AA program. _______________ ...more  
Comment by ScienceFirst on Dec 08, 2022 10:15pm
Below, so many similarities with the type of our NMIBC study.  And we have much higher CRs.  And much higher DRs. Already being superior to KEYTRUDA, FGPFUD should have had the critical regard to question why analyst Uddin didn't come up with any minimum exhaustive research comparing our CR % with recent CR % of recently AA winners, considering how AA can be a game changer for a ...more  
Comment by ScienceFirst on Dec 08, 2022 10:33pm
Below is another recent Accelerated Approval example showing only a 3% CR that you would have expected analyst Uddin to put into perspectives and annexed to its report analysis so his Clients could be in a better position to assess the magnitude of our CR %.  FGPFUD should have had this basic critical stance toward the report of analyst Uddin.  But he cannot as he doesn't do ...more  
Comment by ScienceFirst on Dec 08, 2022 10:49pm
That's exactly how our Ph. 2 trial is designed.   10. Accelerated Approval (Subpart H and Subpart E) Considerations ... In BCG-unresponsive NMIBC, a single-arm clinical trial with complete response rate and duration of response as the primary endpoint can provide primary evidence of effectiveness to support a marketing application Source:  The new 2018 ...more  
Comment by ScienceFirst on Dec 20, 2022 10:17pm
Our chances are high, as we fit the definition of the FDA.  Definition that TLT has specifically added to its web site. Taken at the bottom of this TLT webpage:     FDA guidelines (February 2018) for BCG-Unresponsive Non Muscle Invasive Bladder Cancer states that: “In BCG-Unresponsive NMIBC, a single-arm clinical trial with Complete Response (" ...more  
Comment by Infinity on Dec 09, 2022 4:13am
Thanks Eog,  You have hit the nail on the head so to speak.   I believe you have done your research better than many others on this board.  Thank you for your time and sharing your thoughts.  May I ask you to publish the results for the first 12 under treated patients.  I understand that many are still in the clinical program and continuing to place their trust with ...more  
Comment by Yoly900 on Dec 09, 2022 8:11am
This post has been removed in accordance with Community Policy
Comment by Yoly900 on Dec 09, 2022 8:47am
This post has been removed in accordance with Community Policy
Comment by Yoly900 on Dec 09, 2022 8:58am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250